BD (Becton, Dickinson and Company), a global leader in medical technology, is investing $110 million to expand production of its BD Neopak Glass Prefillable Syringes in Columbus, Nebraska. 

 

The move will accelerate biologic and GLP-1 drug delivery while supporting pharmaceutical reshoring in the US, and is expected to create approximately 120 new jobs.

 

“This is good news for Nebraska,” said Sen. Ricketts. “It has the potential to bring over 100 new jobs to our state. This investment further underscores BD's ongoing commitment to keep critical manufacturing in states like Nebraska. I appreciate BD's long-standing partnership with the Cornhusker State.”

 

The BD Neopak Glass Prefillable Syringe platform is designed for the complex needs of biologics and combination products. Available in 1 mL and 2.25 mL formats, the syringes accommodate high-viscosity formulations, ensure drug-container compatibility, and integrate seamlessly with delivery devices and autoinjectors for both clinical and at-home use.

 

“As demand for biologics and GLP-1s accelerates, BD is strengthening its American manufacturing footprint to support U.S.-based drug delivery innovation and supply chain resiliency,” said Patrick Jeukenne, worldwide president of BD Pharmaceutical Systems. 

 

“This investment in Nebraska advances our long-term growth strategy and reflects our commitment to partnering with biopharmaceutical innovators as they bring advanced therapies to patients who require next-generation drug delivery solutions.”

 

BD’s Columbus site will receive $100 million to establish BD Neopak production, with supply expected to begin in mid-2026. An additional $10 million will enhance cannula manufacturing, bringing the total investment to $110 million. These expansions build on BD’s recent $35 million investment in prefilled flush syringe manufacturing in Columbus, which added roughly 50 jobs.

 

With more than 75 years of operations in Columbus, BD’s site remains a cornerstone of the company’s vertically integrated cannula manufacturing network. As the largest medical device manufacturer in the US, BD plans to invest over $2.5 billion in U.S. manufacturing over the next five years.

 

This expansion strengthens US pharmaceutical supply chain resilience by localizing production of the BD Neopak Glass Prefillable Syringe, ensuring continuity, scalability, and faster access to life-changing injectable therapies amid growing demand.